Navigation Links
Mindray Announces Third Quarter 2009 Financial Results
Date:11/9/2009

SHENZHEN, China, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter and nine months ended September 30, 2009.

    Highlights for Operations as of September 30, 2009
    -- Third quarter 2009 net revenues were $151.1 million, an increase of
       3.1% over the third quarter of 2008. First nine months net revenues
       were $445.3 million, an increase of 17.3% year-over-year.
    -- International markets continued to recover in the third quarter of 2009
       with only 1.3% year-over-year decline, backed by stronger growth in
       emerging markets and narrower decline in developed markets.
    -- Fully diluted EPS in the third quarter of 2009 was $0.38, a 56.9%
       increase from the third quarter of 2008 and a 30.6% increase from the
       second quarter of 2009. First nine months fully diluted EPS was $0.90,
       an increase of 33.7% year-over-year.
    -- Fully diluted non-GAAP EPS in the third quarter of 2009 was $0.33, a
       12.2% increase from the third quarter of 2008. First nine months fully
       diluted non-GAAP EPS was $0.94, an increase of 10.7% year-over-year.
    -- EBITDA in the third quarter of 2009 was $60.1 million, a 51.6% increase
       from the third quarter of 2008 and a 28.7% increase from the second
       quarter of 2009.
    -- Gross margin in the third quarter of 2009 was 56.6%, compared to 54.2%
       in the third quarter of 2008 and 57.2% in the second quarter of 2009.
    -- Net operating cash generated during the third quarter of 2009 was $20.9
       million.
    -- Mindray recorded special one-time income of $14.0 million resulting
       from a mutually agreed upon termination of a joint development a
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
2. Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007
3. Mindray to Attend 2007 RSNA Conference in Chicago
4. Mindray to Attend 2008 CLSA Asia Investors Forum
5. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
6. Mindray to Report Fourth Quarter and Fiscal Year 2007 Financial Results on March 5, 2008
7. Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results
8. Mindray to Attend the 11th Credit Suisse Asian Investment Conference
9. Mindrays Laptop-size M5 and BS-200 Receive FDA Clearance
10. Mindray to Attend the JPMorgan 4th Annual China Conference
11. Mindray to Exhibit at 2008 China International Medical Equipment Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Recently, the famous review website, Top10BestSEOHosting.com, has ... . According to the site, GoDaddy, Bluehost and ... the world. “Nowadays, Joomla hosting is a very ... hosting. The account owner is allowed to use ... under a specific name, brand or company,” the ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 The ... ) will be addressed in December, when the U.S. ... hearing session. According to a Hearing Session Order issued ... the matter will be heard on December 4, 2014, ... at 9:30 a.m. (In Re: Xarelto Products Liability Litigation, ...
(Date:10/25/2014)... TASC (Total Administrative Services Corporation), ... account management services, announces the release of four ... taxes, reduce administrative workload, and lessen liability. ... the efficient handling of complex, time-sensitive, and labor-consuming ... meets their goals and objectives. The four Suites ...
(Date:10/25/2014)... October 25, 2014 The federal ... http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific Corp. ... District Court, Southern District of West Virginia has ... Punitive Damages in a group of cases filed ... issued on October 21st, U.S. District Judge Joseph ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: GoDaddy, Bluehost And Hostgator Are Among The Most Excellent Suppliers In The World 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2
... Inviting, Child-Friendly Online Information Source for ... ... http://www.searchhope.org , LOS ANGELES, March ... created an innovative, inviting,child-friendly web-based portal that allows sick children and ...
... damage that can occur in babies with congenital heart disease is ... defect results in too much blood in the lungs, more blood ... blood vessel growth is abruptly halted. , You get this burst ... we think the system gets shut down and the lungs dont ...
... NC Researchers at Duke University Medical Center say ... more harm to cardiovascular health in women than in ... Brain, Behavior and Immunity, found that poor sleep is ... biomarkers associated with elevated risk of heart disease and ...
... The Children,s,Hospital of Philadelphia is pleased to name ... Nursing Officer. The appointment follows an,extensive national search., ... coming to Children,s Hospital, Esposito-Herr served as the ... of Maryland Medical,Center, where she also held a ...
... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... scheduled to,present from 8:30 a.m. to 8:55 a.m. ET, ... Global Healthcare Conference in Miami,Florida., The event will ... web cast,which may be accessed by visiting http://investors.gentiva.com/events.cfm ...
... stunted growth , , MONDAY, March 10 (HealthDay News) -- ... patients at risk for bone damage and stunted growth, ... concerns a signal transduction inhibitor (STI) medication known as ... by short-circuiting tumor growth on the molecular level. The ...
Cached Medicine News:Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 2Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 3Health News:Lung damage in babies with congenital heart disease under study 2Health News:Lung damage in babies with congenital heart disease under study 3Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:The Children's Hospital of Philadelphia Appoints New Chief Nursing Officer 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 3Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 2Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 3
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak Industries, ... developed APLS ® Body Guard Bio, a ... spread of bacteria and virus while protecting service ... Guard Bio features a rugged, external nylon shell, ... create a leak-proof inner chamber that contains contaminated ...
(Date:10/22/2014)... , October 22, 2014 A ... Gloves Market (Product type, Form, End user, Application and ... Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... gloves market. Based on key trends tracked, it is ... at $7.9 billion by 2020, registering a CAGR of ...
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Registration Trials, HAYWARD, Calif., Sept. 6 Kosan ... has successfully,reached a binding agreement with the U.S. Food ... clinical trial, a pivotal Phase 3 trial,of its Hsp90 ... Through the FDA,s Special Protocol Assessment (SPA),process, Kosan and ...
... Prevalence and Continuous,Abstinence by Dose, Schedule and Antibody Response; Nabi to ... ... Today, BOCA RATON, Fla., Sept. 5 Nabi,Biopharmaceuticals (Nasdaq: ... (Nicotine Conjugate Vaccine), the company,s,innovative and proprietary investigational vaccine being developed ...
Cached Medicine Technology:Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 2Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 3Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 4Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 5Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 6Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 7
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: